13 June 2013 | News | By BioSpectrum Bureau
Eisai, Quintiles joint program evaluating effects of lenvatinib (VEGF receptor tyrosine kinase inhibitor and multi-kinase inhibitor) on melanoma shows positive results
Singapore: Eisai has revealed therapeutic effects of lenvatinib (generic name- VEGF receptor tyrosine kinase inhibitor and multi-kinase inhibitor discovered in-house) on melanoma.
The firm confirmed positive effects in one of a series of joint development programs that are being conducted as part of the company's strategic collaboration with Quintiles.
The collaboration agreement was initiated in October 2009, as a new business model aimed at expediting point of care (POC) achievements by conducting multiple programs in parallel to clinically develop Eisai-owned oncology candidate compounds.
Eisai will now begin further clinical study preparations aimed at gaining regulatory approval for lenvatinib in light of the finding while continuing to discuss related developments with relevant health authorities in various countries.
The company remains committed in its collaboration with Quintiles to expediting the early and steady development of novel anticancer compounds in order to further contribute to addressing the unmet medical needs of, and increasing the benefits provided to, patients living with cancer.